title: Should tuberculosis programmes invest in second-line treatments for multidrug-resistant tuberculosis (MDR-TB)?
authors.affiliation: Department of Public Health and Policy, London School of Hygiene and Tropical Medicine, UK.
authors.forename: Richard
authors.initials: R
authors.lastname: Coker
mesh_terms: D000995:Antitubercular Agents / Q000627:therapeutic use*; D003140:Communicable Disease Control / Q000191:economics; D003362:Cost-Benefit Analysis; D003365:Costs and Cost Analysis; D006801:Humans; D018088:Tuberculosis, Multidrug-Resistant / Q000188:drug therapy*
chemical_list: D000995:Antitubercular Agents